NA
AQST icon

NewEdge Advisors’s Aquestive Therapeutics AQST Stock Holding History

NewEdge Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8K Hold
5,000
– – ﹤0.01% 3184
2025
Q4 		$32.3K Hold
5,000
– – ﹤0.01% 3104
2025
Q3 		$27.9K Buy
+5,000
New +$21.6K ﹤0.01% 3011

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NewEdge Advisors's AQST Position: Q1 2026 in Review

NewEdge Advisors held its Aquestive Therapeutics (AQST) position steady in Q1 2026 at 5,000 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

NewEdge Advisors first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. The position peaked at $32.3K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • NewEdge Advisors held 5,000 shares of Aquestive Therapeutics worth $20.8K as of Q1 2026.
  • NewEdge Advisors left its Aquestive Therapeutics share count unchanged in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3184 holding.
  • NewEdge Advisors first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • NewEdge Advisors's Aquestive Therapeutics position peaked at $32.3K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.